Usefulness of the α1-blocker doxazosin as a third-line antihypertensive drug

Hypertension Research

Volumn 30, Issue 4, 2007, Pages 301-306

  Ohta, Yuko ^a   Tsuchihashi, Takuya ^a   Onaka, Uran ^a   Eto, Kimika ^a   Ueno, Michio ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

1 blocker; Antihypertensive drug; Combination therapy

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; JAPAN; LOW DRUG DOSE; MALE; OBESITY; PREVALENCE; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34249109074     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.301     Document Type: Article

References (26)

1. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hyperetrision: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
2. Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coodination Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
3. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
4. Bakris G: Maximizing cardiorenal benefit in the management of hypertension: achieving blood pressure goals. J Clin Hypertens 1999; 1: 141-147.
5. Cushman WC, Ford CE, Cutler JA, et al: Success and predictors of blood pressure control in diverse north America settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.
6. Ferrara LA, Marino LD, Russo O, Marotta T, Mancini M, on behalf of the DoCHH Study Group: Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The doxazosin-captopril in hypercholesterolemic hypertensive study. Hypertension 1993; 21: 97-104.
7. Rosenthal J: Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. Am Heart J 1988; 116: 1763-1766.
8. Shieh SM, Shen WHH, Shen DC, Fuh MMT, Chen YDI, Reaven GM: Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992; 5: 827-831.
9. Levy D, Walmsley P, Levenstein M, for the Hypertension and Lipid Trial Study Group: Principal results of the hypertension and lipid trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131: 966-973.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-fisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
11. Troffa C, Manunta P, Fulgheri PD, et al: Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994; 55: 22-31.
12. Searle M, Dathan R, Dean S, Christensen CC, Westheim A: Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990; 39: 299-300.
13. Donnelly R, Elliott HL, Meredith PA, Howie CA, Reid JL: Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992; 19: 479-486.
14. Englert RG, Mauersberger H: A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988; 116: 1826-1832.
15. Lindner UK, Manteuffel GE, Stafunsky M: The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988; 116: 1814-1820.
16. Black HR, Sollins JS, Garofalo JL: The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13: 468-474.
17. Ohta Y, Tsuchihashi T, Ueno M, et al: Relationship between the awareness of salt restriction and the actual salt intake in hypertensive patients. Hypertens Res 2004; 27: 243-246.
18. Ohta Y, Tsuchibashi T, Onaka U, Eto K, Tominaga M, Ueno M: Long-term compliance of salt restriction in Japanese hypertensive patients. Hypertens Res 2005; 28: 953-957.
19. Danhlöf B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenorol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
20. Miura Y, Watanabe M, Yoshinaga K, on behalf of the Japanese Doxazosin Study Group: An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction. Am Heart J 1991; 121: 381-388.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
22. Pickering TG, Levenstein M, Walmsley P, for the Hypertension and Lipid Trial Study Group: Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Result of the HALT study. Am J Hypertens 1994; 7: 844-847.
23. Kario K, Schwartz JE, Pickering TG: Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of α-adrenergic blocker, doxazosin. Results from the HALT study. Hypertension 2000; 35: 787-794.
24. Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
25. Kario K, Pickering TG, Hoshide S, et al: Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system. Am J Hypertens 2004; 17: 668-675.
26. Toyonaga S, Nakatsu T, Suezawa C, Matsubara H, Sogou T, Kusachi S: Relationship between body mass index and anti-hypertensive efficacy of doxazosin according to a survey of Japanese patients. J Intern Med Res 2004; 32: 176-184.